While AdvaMed said in a written statement last month that the Biden administration’s plan to purchase 500 million rapid COVID-19 tests and make them available for free was an “encouraging” step, the medtech lobby emphasized that the federal government plays a “pivotal role of guaranteeing the market,” and going forward more must be done to ensure a consistent and reliable supply of diagnostics.